Results 121 to 130 of about 12,328 (175)

Treatment of human African trypanosomiasis

open access: yesBulletin of the World Health Organization
Michel Dumas, Bernard Bouteille
doaj   +1 more source

Effectiveness and safety of fexinidazole for gambiense human African trypanosomiasis and exploration of adherence in outpatients: a phase 3b, prospective, open-label, non-randomised, cohort study.

open access: yesLancet Glob Health
Kumeso VKB   +21 more
europepmc   +1 more source

Interleukin 21 is a marker of Human African Trypanosomiasis Infection and a contributor to pathology in mice

open access: yes
Capewell P   +10 more
europepmc   +1 more source

Control of human African trypanosomiasis in the Quiçama focus, Angola

open access: yesBulletin of the World Health Organization, 2002
Ruiz José Antonio   +2 more
doaj  

A Genome-Wide Association Study Reveals Novel Genetic Markers Associated with Human African Trypanosomiasis

open access: yes
Mulindwa J   +33 more
europepmc   +1 more source

Human African Trypanosomiasis

Infectious Disease Clinics of North America, 2012
Abstract Human African trypanosomiasis (sleeping sickness) is caused by subspecies of the protozoan parasite Trypanosoma brucei. The disease is restricted to tropical Africa where it is transmitted by the bite of infected tsetse flies (Glossina spp.).
Johannes Blum
exaly   +4 more sources

Human African trypanosomiasis

Lancet, The
Human African trypanosomiasis or sleeping sickness is caused by infection with Trypanosoma brucei gambiense or Trypanosoma brucei rhodesiense parasites, which are transmitted by tsetse flies in sub-Saharan Africa. Control of human African trypanosomiasis is based on case detection, treatment, and vector control.
Ak Lindner, Franco JOSÉ R
exaly   +3 more sources

Home - About - Disclaimer - Privacy